SUBSCRIBE
SUBSCRIBE
News   Business

Boehringer Ingelheim Corporation to Buy U.S. Biotech Company Actimis Pharmaceuticals, Inc. for Up to $515M

June 17, 2008 | 
1 min read

FRANKFURT (Reuters) - Boehringer Ingelheim will buy privately owned Actimis Pharmaceuticals for $515 million if the U.S. biotech company could successfully develop its asthma compound, the German drugmaker said on Tuesday.

Alliances Mergers & acquisitions Europe
MORE ON THIS TOPIC
cutting off a row of people into pieces
Layoffs
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
December 12, 2024
 · 
205 min read
 · 
BioSpace Editorial Staff
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac